Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

Bristol Myers Squibb (BMY) Stock Looks Below Fair Value Following A 41% ...

Drug approval Earnings report Financial outlook AI-generated analysis

πŸ“ˆ BMY stock has returned approximately 40.5% over the past three years, trading near $62.91 per share.

πŸ’° The company generated about $9.3 billion in free cash flow over the last twelve months according to the analysis.

πŸ”¬ Recent positive data for Camzyos and new approvals for ZENBEXUS are expected to support future drug-driven cash flows.

⚠️ Investors face a projected revenue step-down from Eliquis beginning in 2027 as part of the company's lifecycle management.

πŸ’‘ A bullish narrative suggests BMY is 21% undervalued if late-stage platforms like CAR-T and ADCs succeed commercially.

πŸ“‰ A bearish perspective argues the stock is 121% overvalued at current levels, with price being the primary sticking point.

πŸ’Έ The company has implemented a plan to generate $2 billion in cost savings to offset revenue shifts.

🧠 Simply Wall St analysis indicates the fair value depends on successfully converting late-stage platforms into meaningful products.

Bullish Signals
  • Recent trial results for Camzyos and new product approvals for ZENBEXUS are expected to support expectations for future drug-driven cash flows.
  • The company has a solid pipeline story with late-stage platforms in areas like CELMoDs, CAR-T, ADCs, Factor XI inhibition, and neuroscience that could convert into commercially meaningful products.
  • A bullish analyst narrative suggests the stock is 21% undervalued if the company successfully manages revenue transitions from legacy assets like Eliquis.
Risk Factors
  • The DCF model assumes a gently declining free cash flow pattern over the next decade as major products mature and new launches fill gaps only gradually.
  • A bearish investor narrative argues the stock is 121% overvalued at current levels, stating that the entry price exceeds fair value filters despite the company's quality.
  • The analysis projects a step-down in revenue from Eliquis starting in 2027, which constrains growth assumptions in the valuation model.
Full Analysis
Bristol-Myers Squibb (BMY) shares have appreciated approximately 40.5% over the past three years, trading around $62.91 per share. The article analyzes whether this valuation is justified by the company's long-term cash flow generation capabilities, utilizing a Discounted Cash Flow (DCF) model that projects free cash flow of roughly $9.3 billion over the last twelve months. The analysis suggests BMY may be undervalued based on intrinsic value calculations derived from its cash flow profile. Key drivers supporting this view include recent positive trial results for Camzyos and new product approvals for ZENBEXUS, which are expected to bolster future drug-driven cash flows despite anticipated revenue declines from the legacy asset Eliquis starting in 2027. Simply Wall St presents a split narrative regarding BMY's fair value. A bullish perspective argues the stock is 21% undervalued if the company successfully commercializes its late-stage platforms in areas like CAR-T and ADCs while managing revenue transitions. Conversely, a bearish view contends the stock is 121% overvalued at current levels, citing that the entry price exceeds fair value filters despite the underlying quality of the business. The article concludes by emphasizing the importance of leadership strategy in shaping BMY's future trajectory. It notes that while the company has a solid pipeline and cost-saving plans totaling $2 billion, investors must weigh these factors against the specific assumptions regarding growth margins and earnings required to justify the current market price.